Long-term outcome of treatment with infl
✍
Valérie Crombé; Julia Salleron; Guillaume Savoye; Jean-Louis Dupas; Gwénola Vern
📂
Article
📅
2011
🏛
John Wiley and Sons
🌐
English
⚖ 549 KB
Background: We examined short-and long-term benefits and safety of infliximab (IFX) in a population-based cohort of Crohn's disease (CD) patients <17 years old at diagnosis. ## Methods: The following parameters were assessed: short-and long-term efficacy of IFX, impact of drug efficacy, and mode